Literature DB >> 21479812

Comparative analysis of oncofetal fibronectin and tenascin-C expression in right atrial auricular and left ventricular human cardiac tissue from patients with coronary artery disease and aortic valve stenosis.

Anja Baldinger1, Bernhard R Brehm, Petra Richter, Torsten Bossert, Katja Gruen, Khosro Hekmat, Hartwig Kosmehl, Dario Neri, Hans-Reiner Figulla, Alexander Berndt, Marcus Franz.   

Abstract

Aortic valve stenosis (AVS) and coronary artery disease (CAD) are accompanied by changes in the cardiac extra cellular matrix (cECM) including the re-expression of oncofetal fibronectin (Fn) and tenascin-C (Tn-C) variants. Human antibodies against these variants are usable for targeted therapy. Aim of the study was the comparative analysis of cECM remodelling in tissue samples from right atrial auricle (RAA) and left ventricular septum (LVS). RAA and LVS specimens from 30 patients (17 × AVS; 13 × AVS+CAD) were analysed with respect to histological changes and ECM remodelling using PCR based ECM gene expression profiling. Re-expression of ED-A(+) Fn and A1(+) Tn-C was investigated on the mRNA and on the protein level. For immunofluorescence, human recombinant small immunoprotein (SIP) format antibodies were used. There was a positive correlation of the grade of histological changes in RAA and corresponding LVS samples (r = 0.695). ECM gene expression levels were higher in LVS compared to RAA. For 24 genes, a corresponding relevant (>2.5-fold) up- or down-regulation in RAA and LVS occurred. Using SIP antibodies, a positive correlation of protein deposition levels in RAA and corresponding LVS (r = 0.818) could be shown for ED-A(+) Fn. Cardiac tissue remodelling is likely a process involving the entire heart reflected by intra-individually comparable histology and cECM changes in RAA and LVS samples. ED-A(+) Fn might be an excellent target for an antibody-mediated delivery of diagnostic or therapeutic agents. The RAA is a valuable and representative tool to evaluate cardiac remodelling and to plan individualized therapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21479812     DOI: 10.1007/s00418-011-0809-z

Source DB:  PubMed          Journal:  Histochem Cell Biol        ISSN: 0948-6143            Impact factor:   4.304


  36 in total

Review 1.  Ligand-based vascular targeting of disease.

Authors:  Jascha-N Rybak; Eveline Trachsel; Jörg Scheuermann; Dario Neri
Journal:  ChemMedChem       Date:  2007-01       Impact factor: 3.466

2.  Gene expression analysis of ischemic and nonischemic cardiomyopathy: shared and distinct genes in the development of heart failure.

Authors:  Michelle M Kittleson; Khalid M Minhas; Rafael A Irizarry; Shui Q Ye; Gina Edness; Elayne Breton; John V Conte; Gordon Tomaselli; Joe G N Garcia; Joshua M Hare
Journal:  Physiol Genomics       Date:  2005-03-15       Impact factor: 3.107

3.  A quantitative co-localization analysis of large unspliced tenascin-C(L) and laminin-5/gamma2-chain in basement membranes of oral squamous cell carcinoma by confocal laser scanning microscopy.

Authors:  Marcus Franz; Torsten Hansen; Laura Borsi; Christiane Geier; Peter Hyckel; Peter Schleier; Petra Richter; Annelore Altendorf-Hofmann; Hartwig Kosmehl; Alexander Berndt
Journal:  J Oral Pathol Med       Date:  2007-01       Impact factor: 4.253

Review 4.  Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling.

Authors:  J N Cohn; R Ferrari; N Sharpe
Journal:  J Am Coll Cardiol       Date:  2000-03-01       Impact factor: 24.094

5.  Global gene expression profiling of end-stage dilated cardiomyopathy using a human cardiovascular-based cDNA microarray.

Authors:  J David Barrans; Paul D Allen; Dimitrios Stamatiou; Victor J Dzau; Choong-Chin Liew
Journal:  Am J Pathol       Date:  2002-06       Impact factor: 4.307

6.  Genomic profiling of the human heart before and after mechanical support with a ventricular assist device reveals alterations in vascular signaling networks.

Authors:  Jennifer L Hall; Suzanne Grindle; Xinqiang Han; David Fermin; Soon Park; Yingjie Chen; Robert J Bache; Ami Mariash; Zhanjun Guan; Sofia Ormaza; Jeanne Thompson; Judith Graziano; Shireen E de Sam Lazaro; Shuchong Pan; Robert D Simari; Leslie W Miller
Journal:  Physiol Genomics       Date:  2004-05-19       Impact factor: 3.107

Review 7.  Arterial remodeling in vascular disease: a key role for hyaluronan and versican.

Authors:  Thomas N Wight
Journal:  Front Biosci       Date:  2008-05-01

8.  Microarray gene expression profiles in dilated and hypertrophic cardiomyopathic end-stage heart failure.

Authors:  Juey-Jen Hwang; Paul D Allen; George C Tseng; Ching-Wan Lam; Lameh Fananapazir; Victor J Dzau; Choong-Chin Liew
Journal:  Physiol Genomics       Date:  2002-07-12       Impact factor: 3.107

Review 9.  Anti-vascular tumor therapy: recent advances, pitfalls and clinical perspectives.

Authors:  Martin E Eichhorn; Sebastian Strieth; Marc Dellian
Journal:  Drug Resist Updat       Date:  2004-04       Impact factor: 18.500

10.  Gene expression signals involved in ischemic injury, extracellular matrix composition and fibrosis defined by global mRNA profiling of the human left ventricular myocardium.

Authors:  Anders Gabrielsen; Patrick R Lawler; Wang Yongzhong; Daniel Steinbrüchel; Dimo Blagoja; Gabrielle Paulsson-Berne; Jens Kastrup; Göran K Hansson
Journal:  J Mol Cell Cardiol       Date:  2007-01-08       Impact factor: 5.000

View more
  8 in total

Review 1.  Recent progress in histochemistry and cell biology.

Authors:  Stefan Hübner; Athina Efthymiadis
Journal:  Histochem Cell Biol       Date:  2012-02-25       Impact factor: 4.304

Review 2.  Tenascin-C in cardiovascular remodeling: potential impact for diagnosis, prognosis estimation and targeted therapy.

Authors:  Marcus Franz; Christian Jung; Alexander Lauten; Hans R Figulla; Alexander Berndt
Journal:  Cell Adh Migr       Date:  2015       Impact factor: 3.405

3.  De novo expression of fetal ED-A(+) fibronectin and B (+) tenascin-C splicing variants in human cardiac allografts: potential impact for targeted therapy of rejection.

Authors:  Marcus Franz; Monika Matusiak-Brückner; Petra Richter; Katja Grün; Barbara Ziffels; Dario Neri; Hansjörg Maschek; Uwe Schulz; Alexander Pfeil; Christian Jung; Hans R Figulla; Jan Gummert; Alexander Berndt; André Renner
Journal:  J Mol Histol       Date:  2014-05-03       Impact factor: 2.611

4.  Detection of Soluble ED-A(+) Fibronectin and Evaluation as Novel Serum Biomarker for Cardiac Tissue Remodeling.

Authors:  Barbara Ziffels; Johanna Ospel; Katja Grün; Dario Neri; Alexander Pfeil; Michael Fritzenwanger; Hans R Figulla; Christian Jung; Alexander Berndt; Marcus Franz
Journal:  Dis Markers       Date:  2016-08-18       Impact factor: 3.434

5.  Lung tissue remodelling in MCT-induced pulmonary hypertension: a proposal for a novel scoring system and changes in extracellular matrix and fibrosis associated gene expression.

Authors:  Marcus Franz; Katja Grün; Stefan Betge; Ilonka Rohm; Bernadin Ndongson-Dongmo; Reinhard Bauer; P Christian Schulze; Michael Lichtenauer; Iver Petersen; Dario Neri; Alexander Berndt; Christian Jung
Journal:  Oncotarget       Date:  2016-12-06

6.  Integrated Analysis of LncRNA-Mediated ceRNA Network in Calcific Aortic Valve Disease.

Authors:  Long Chen; Ke Wei; Jun Li; Yue Li; Huiqing Cao; Zhe Zheng
Journal:  Cells       Date:  2022-07-14       Impact factor: 7.666

7.  Increased Serum Levels of Fetal Tenascin-C Variants in Patients with Pulmonary Hypertension: Novel Biomarkers Reflecting Vascular Remodeling and Right Ventricular Dysfunction?

Authors:  Ilonka Rohm; Katja Grün; Linda Marleen Müller; Daniel Kretzschmar; Michael Fritzenwanger; Atilla Yilmaz; Alexander Lauten; Christian Jung; P Christian Schulze; Alexander Berndt; Marcus Franz
Journal:  Int J Mol Sci       Date:  2017-11-08       Impact factor: 5.923

Review 8.  Pulmonary Arterial Stiffness: An Early and Pervasive Driver of Pulmonary Arterial Hypertension.

Authors:  Wei Sun; Stephen Y Chan
Journal:  Front Med (Lausanne)       Date:  2018-07-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.